Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01020331 · ClinicalTrials.gov registry record · Phase 2
Memantine Therapy in Amyotrophic Lateral Sclerosis
A Phase 2 study, sponsored by Phoenix Neurological Associates.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT01020331 is a Phase 2 study that has completed, run by Phoenix Neurological Associates. The registered enrollment target is 20 participants.
The verdict
NCT01020331, a Phase 2 study, has completed, sponsored by Phoenix Neurological Associates.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
Tau, a protein in the cerebrospinal fluid CSF is believed to be elevated in amyotrophic lateral sclerosis (ALS) patients. The investigators believe that Tau is truly a marker of increased neuronal death from any disease process. It is been shown that Memantine can inhibit and reverse the abnormal hyperphosphorylation of Tau and therefore the investigators are looking at the efficacy of Memantine at 10 mg twice a day (BID) to see if disease progression correlates with possible changes in Tau in ALS patients based on ALS Functional Rating Scale (ALSFRS) scores.
Interventions
- DRUG Memantine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2005-06 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01020331
The ClinicalTrials.gov registry entry for NCT01020331 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Phoenix Neurological Associates, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Memantine is the first listed.
NCT01020331 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01020331 about?
NCT01020331 is a clinical study titled "Memantine Therapy in Amyotrophic Lateral Sclerosis". Tau, a protein in the cerebrospinal fluid CSF is believed to be elevated in amyotrophic lateral sclerosis (ALS) patients. The investigators believe that Tau is truly a marker of increased neuronal death from any disease process. It is been shown that Memantine can inhibit and reverse the abnormal hy...
What is the current status of trial NCT01020331?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2005-06. Estimated completion is 2009-10.
What interventions are being tested in trial NCT01020331?
The interventions under investigation include: Memantine (DRUG).
Who is sponsoring clinical trial NCT01020331?
This trial is sponsored by Phoenix Neurological Associates, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.